Our Pipeline

The information below is only presented for the purposes of providing a general overview of our clinical trials. Other than where specifically noted, these compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration.

Wholly-owned U.S. Wholly-owned Collaboration
COMPOUND (Partner)
Phase 1 Phase 2 Phase 3
Or Registration Trial
APPROVED
BRAFTOVI® (encorafenib) capsules +
MEKTOVI® (binimetinib) tablets
Disease State: BRAF-mutant unresectable or metastatic melanoma Target: BRAF + MEK
Approved in US & EU
    Approved in US & EU
Binimetinib (Ono, Pierre Fabre) Disease State: Cancer Target: MEK
Phase 3
   
Encorafenib (Ono, Pierre Fabre) Disease State: Cancer Target: BRAF
Phase 3
   
Selumetinib (AstraZeneca) Disease State: NF1 Target: MEK
Phase 3
   
Ipatasertib (Genentech) Disease State: Cancer Target: AKT
Phase 3
   
Varlitinib (ASLAN) Disease State: Cancer Target: Pan-HER
Phase 3
   
Danoprevir (Roche) Disease State: Hepatitis C Target: NS3 Protease
Approved in China
    Approved in China
ARRY-797 Disease State: LMNA-related DCM Target: p38
Phase 3
   
Larotrectinib* (Loxo Oncology) Disease State: Cancer Target: PanTrk
Phase 3
   
Tucatinib* (Seattle Genetics) Disease State: Cancer Target: HER-2
Phase 3
   
LOXO-292* (Loxo Oncology) Disease State: Cancer Target: Ret
Phase 3
   
ARRY-382 Disease State: Cancer Target: CSF1R
Phase 2
  
Motolimod (Celgene) Disease State: Cancer Target: TLR
Phase 2
  
Prexasertib (Eli Lilly) Disease State: Cancer Target: Chk1
Phase 2
  
LOXO-195 (Loxo Oncology) Disease State: Cancer Target: Trk
Phase 1
 
AK-1830 (Asahi Kasei Pharma) Disease State: Inflammation Target: Trk
Phase 1
 

*Phase 2 registration trials

Expanded Access Policy
Array BioPharma Expanded Access Policy.pdf
arraybiopharma@druginfo.com

Continuing Medical Education / Grant Requests
Array BioPharma Guidelines for the Support of Independent Medical Education.pdf
CME@arraybiopharma.com

LEARN MORE

Find out more about the Phase 3
BEACON CRC trial